Search - tctmd.com

Displaying 301 - 320 of 595

Sort: Relevancy | Date

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

Cumulative Burden of LDL Cholesterol Increases CHD Risk

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

Early Menopause Linked to Increased ASCVD Risk

News Daily News

Early Menopause Linked to Increased ASCVD Risk

September 17, 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

Heterozygous FH Diagnosed Late, Remains Undertreated

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

Could an App Replace Statin Prescribing by Doctors?

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

Number of People With Hypertension Doubles Since 1990

News Daily News

Number of People With Hypertension Doubles Since 1990

August 26, 2021

ASCVD.food.insecurity.jpg

News Daily News

Food Insecurity Common Among Patients With ASCVD

Michael O'Riordan

August 18, 2021

Milrinone, Dobutamine Comparable for Cardiogenic Shock: DOREMI

News Daily News

Milrinone, Dobutamine Comparable for Cardiogenic Shock: DOREMI

August 10, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

News Daily News

Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited

Michael O'Riordan

August 03, 2021

Statin Decisions Gain From Scoring of Coronary Artery Calcium: MESA

News Daily News

Statin Decisions Gain From Scoring of Coronary Artery Calcium: MESA

Yael L. Maxwell

July 21, 2021

Apixaban May Be Best DOAC for Frail, Older Patients With AF

News Daily News

Apixaban May Be Best DOAC for Frail, Older Patients With AF

July 19, 2021

Making the Case for Sex-Specific CVD Guidelines

News Daily News

Making the Case for Sex-Specific CVD Guidelines

July 08, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.